Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma.

Méndez-Vidal MJ, Molina Á, Anido U, Chirivella I, Etxaniz O, Fernández-Parra E, Guix M, Hernández C, Lambea J, Montesa Á, Pinto Á, Ros S, Gallardo E.

BMC Pharmacol Toxicol. 2018 Nov 26;19(1):77. doi: 10.1186/s40360-018-0264-8.

2.

Weekly cabazitaxel plus prednisone is effective and less toxic for 'unfit' metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial.

Climent MÁ, Pérez-Valderrama B, Mellado B, Fernández Parra EM, Fernández Calvo O, Ochoa de Olza M, Muinelo Romay L, Anido U, Domenech M, Hernando Polo S, Arranz Arija JÁ, Caballero C, Juan Fita MJ, Castellano D.

Eur J Cancer. 2017 Dec;87:30-37. doi: 10.1016/j.ejca.2017.09.028. Epub 2017 Nov 2.

PMID:
29102858
3.

Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients.

León-Mateos L, Casas H, Abalo A, Vieito M, Abreu M, Anido U, Gómez-Tato A, López R, Abal M, Muinelo-Romay L.

Oncotarget. 2017 May 19;8(33):54708-54721. doi: 10.18632/oncotarget.18025. eCollection 2017 Aug 15.

4.

A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01).

García-Donas J, Leon LA, Esteban E, Vidal-Mendez MJ, Arranz JA, Garcia Del Muro X, Basterretxea L, González Del Alba A, Climent MA, Virizuela JA, Álvarez C, Sepúlveda J, Anido U, López C, Ortiz-Morales MJ, Pérez X, Rodriguez-Antona C, Rodriguez-Moreno JF, Hernando S, Castellano D.

Eur Urol Focus. 2017 Oct;3(4-5):430-436. doi: 10.1016/j.euf.2016.09.004. Epub 2016 Oct 4.

PMID:
28753791
5.

Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.

García-Donas J, Font A, Pérez-Valderrama B, Virizuela JA, Climent MÁ, Hernando-Polo S, Arranz JÁ, Del Mar Llorente M, Lainez N, Villa-Guzmán JC, Mellado B, González Del Alba A, Castellano D, Gallardo E, Anido U, García Del Muro X, Domènech M, Puente J, Morales-Barrera R, Pérez-Gracia JL, Bellmunt J.

Lancet Oncol. 2017 May;18(5):672-681a. doi: 10.1016/S1470-2045(17)30242-5. Epub 2017 Apr 4. Erratum in: Lancet Oncol. 2019 Jan;20(1):e9.

PMID:
28389316
6.

Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome.

Ruiz-Bañobre J, Abdulkader I, Anido U, León L, López-López R, García-González J.

APMIS. 2017 Mar;125(3):259-263. doi: 10.1111/apm.12658. No abstract available.

PMID:
28233446
7.

Long-term Response to Nivolumab and Acute Renal Failure in a Patient with Metastatic Papillary Renal Cell Carcinoma and a PD-L1 Tumor Expression Increased with Sunitinib Therapy: A Case Report.

Ruiz-Bañobre J, Anido U, Abdulkader I, Antúnez-López J, López-López R, García-González J.

Front Oncol. 2016 Nov 22;6:250. eCollection 2016.

8.

Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).

García J, Santomé L, Anido U, Fernández-Calvo O, Afonso-Afonso J, Lázaro M, Medina A, Vázquez Estévez S.

Curr Oncol Rep. 2016 Dec;18(12):72. Review.

PMID:
27812861
9.

Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial.

Robles NR, Peces R, Gómez-Ferrer Á, Villacampa F, Álvarez-Ossorio JL, Pérez-Segura P, Morote J, Herrera-Imbroda B, Nieto J, Carballido J, Anido U, Valero M, Meseguer C, Torra R.

Orphanet J Rare Dis. 2016 Sep 26;11(1):128.

10.

Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back.

León-Mateos L, Vieito M, Anido U, López López R, Muinelo Romay L.

Int J Mol Sci. 2016 Sep 20;17(9). pii: E1580. Review.

11.

The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma.

Lambea J, Anido U, Etxániz O, Flores L, Montesa Á, Sepúlveda JM, Esteban E.

Curr Oncol Rep. 2016 Nov;18(11):66. doi: 10.1007/s11912-016-0553-6. Review.

PMID:
27613167
13.

Evaluation of Circulating Tumor Cells and Related Events as Prognostic Factors and Surrogate Biomarkers in Advanced NSCLC Patients Receiving First-Line Systemic Treatment.

Muinelo-Romay L, Vieito M, Abalo A, Nocelo MA, Barón F, Anido U, Brozos E, Vázquez F, Aguín S, Abal M, López RL.

Cancers (Basel). 2014 Jan 21;6(1):153-65. doi: 10.3390/cancers6010153.

14.

A logistic model for the detection of circulating tumour cells in human metastatic colorectal cancer.

Barbazán J, Vieito M, Abalo A, Alonso-Alconada L, Muinelo-Romay L, Alonso-Nocelo M, León L, Candamio S, Gallardo E, Anido U, Doll A, de los Ángeles Casares M, Gómez-Tato A, Abal M, López-López R.

J Cell Mol Med. 2012 Oct;16(10):2342-9. doi: 10.1111/j.1582-4934.2012.01544.x.

15.

Evaluation of clinical use and effectiveness of darbepoetin alfa in cancer patients with chemotherapy-induced anemia.

Bustos A, Álvarez R, Aramburo PM, Carabantes F, Díaz N, Florián J, Lázaro M, de Segovia JM, Gasquet JA, Alegre A; RADAR Study Group.

Curr Med Res Opin. 2012 Jan;28(1):57-67. doi: 10.1185/03007995.2011.639352. Epub 2011 Nov 23.

PMID:
22070513
16.

High-risk endometrial carcinoma profiling identifies TGF-β1 as a key factor in the initiation of tumor invasion.

Muinelo-Romay L, Colas E, Barbazan J, Alonso-Alconada L, Alonso-Nocelo M, Bouso M, Curiel T, Cueva J, Anido U, Forteza J, Gil-Moreno A, Reventos J, Lopez-Lopez R, Abal M.

Mol Cancer Ther. 2011 Aug;10(8):1357-66. doi: 10.1158/1535-7163.MCT-10-1019. Epub 2011 May 25.

17.

X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.

Lamas MJ, Duran G, Gomez A, Balboa E, Anido U, Bernardez B, Rana-Diez P, Lopez R, Carracedo A, Barros F.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):138-44. doi: 10.1016/j.ijrobp.2010.09.053. Epub 2010 Dec 16.

PMID:
21167658
18.

Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study.

Cueva JF, Calvo M, Anido U, León L, Gallardo E, Areses C, Bernárdez B, Gayoso L, García J, Jesús Lamas M, Curiel T, Vázquez F, Candamio S, Vidal Y, Javier Barón F, López R.

Invest New Drugs. 2012 Apr;30(2):688-94. doi: 10.1007/s10637-010-9539-7. Epub 2010 Sep 16.

PMID:
20844926
19.

Poxviral-based prostate-specific antigen vaccine in prostate cancer.

León L, Areses MC, Anido U, Gómez A, Carballo AM.

J Clin Oncol. 2010 Aug 20;28(24):e416; author reply e417. doi: 10.1200/JCO.2010.29.1070. Epub 2010 Jun 21. No abstract available.

PMID:
20566998

Supplemental Content

Loading ...
Support Center